Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,696 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction.
Matsue Y, Ter Maaten JM, Suzuki M, Torii S, Yamaguchi S, Fukamizu S, Ono Y, Fujii H, Kitai T, Nishioka T, Sugi K, Onishi Y, Noda M, Kagiyama N, Satoh Y, Yoshida K, van der Meer P, Damman K, Voors AA, Goldsmith SR. Matsue Y, et al. Among authors: ono y. Clin Res Cardiol. 2017 Oct;106(10):802-812. doi: 10.1007/s00392-017-1122-1. Epub 2017 May 24. Clin Res Cardiol. 2017. PMID: 28540483 Free PMC article. Clinical Trial.
Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure: design and rationale of the AQUAMARINE study.
Matsue Y, Suzuki M, Nagahori W, Yoshida K, Onishi Y, Satoh Y, Ono Y, Nishioka T, Noda M, Sugi K, Torii S, Tejima T, Sakurada H, Yamaguchi S, Okishige K, Fujii H, Takahashi A. Matsue Y, et al. Among authors: ono y. Cardiovasc Drugs Ther. 2014 Feb;28(1):73-7. doi: 10.1007/s10557-013-6491-8. Cardiovasc Drugs Ther. 2014. PMID: 24048511 Clinical Trial.
Corrigendum to "Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction" Journal of Cardiac Failure, Vol. 22, No. 6, June 2016, pp. 423-432.
Matsue Y, Suzuki M, Torii S, Yamaguchi S, Fukamizu S, Ono Y, Fujii H, Kitai T, Nishioka T, Sugi K, Onishi Y, Noda M, Kagiyama N, Satoh Y, Yoshida K, Goldsmith SR. Matsue Y, et al. Among authors: ono y. J Card Fail. 2016 Nov;22(11):941. doi: 10.1016/j.cardfail.2016.07.434. Epub 2016 Jul 29. J Card Fail. 2016. PMID: 27481596 No abstract available.
Prognostic importance of sodium level trajectory in acute heart failure.
Matsue Y, Yoshioka K, Suzuki M, Torii S, Yamaguchi S, Fukamizu S, Ono Y, Fujii H, Kitai T, Nishioka T, Sugi K, Onishi Y, Noda M, Kagiyama N, Satoh Y, Yoshida K, Goldsmith SR. Matsue Y, et al. Among authors: ono y. Heart Vessels. 2017 Dec;32(12):1498-1505. doi: 10.1007/s00380-017-1020-5. Epub 2017 Jul 11. Heart Vessels. 2017. PMID: 28698994 Clinical Trial.
Peri-procedural anticoagulation in patients with end-stage kidney disease undergoing atrial fibrillation ablation: results from the multicentre end-stage kidney disease-atrial fibrillation ablation registry.
Yamamoto T, Miyazaki S, Tanaka Y, Kono T, Nakata T, Mizukami A, Aoyama D, Arai H, Taomoto Y, Horie T, Hojo R, Kawamoto S, Yabe K, Akiyoshi K, Kato N, Ono Y, Suzuki A, Fukamizu S, Nagata Y, Yamauchi Y, Tada H, Hachiya H, Inaba O, Takahashi A, Goya M, Sasano T. Yamamoto T, et al. Among authors: ono y. Europace. 2023 Apr 15;25(4):1400-1407. doi: 10.1093/europace/euad056. Europace. 2023. PMID: 36892146 Free PMC article.
Adjunctive posterior wall isolation for the treatment of persistent and longstanding persistent atrial fibrillation (CORNERSTONE AF) trial: Design and rationale.
Shigeta T, Miyazaki S, Inaba O, Inamura Y, Nitta J, Sekiguchi Y, Takahashi A, Hachiya H, Nagata Y, Yamauchi Y, Hayashi T, Iwai S, Mizukami A, Ono Y, Handa K, Suzuki M, Suzuki A, Nakajima J, Hirao K, Okada H, Negishi M, Ikenouchi T, Yamamoto T, Goto K, Nishimura T, Tao S, Takigawa M, Hirakawa A, Goya M, Sasano T. Shigeta T, et al. Among authors: ono y. Clin Cardiol. 2024 Jan;47(1):e24164. doi: 10.1002/clc.24164. Epub 2023 Oct 11. Clin Cardiol. 2024. PMID: 37822107 Free PMC article.
Incidence of phrenic nerve injury during pulmonary vein isolation using different cryoballoons: data from a large prospective ablation registry.
Tachibana S, Miyazaki S, Nitta J, Shirai Y, Nagata Y, Sagawa Y, Sekiguchi Y, Inamura Y, Sasaki T, Yamauchi Y, Inaba O, Ono Y, Suzuki M, Suzuki A, Iwai S, Okada H, Mizukami A, Azegami K, Hachiya H, Handa K, Goto K, Nishimura T, Hirao K, Takahashi A, Sasano T. Tachibana S, et al. Among authors: ono y. Europace. 2024 Mar 30;26(4):euae092. doi: 10.1093/europace/euae092. Europace. 2024. PMID: 38588039 Free PMC article.
Synergistic effect of combined HMG-CoA reductase inhibitor and angiotensin-II receptor blocker therapy in patients with chronic heart failure: the HF-COSTAR trial.
Maejima Y, Nobori K, Ono Y, Adachi S, Suzuki J, Hirao K, Isobe M, Ito H; Heart Failure by Coadministration of Statin and Angiotensin-II Receptor Blocker (HF-COSTAR) Trial Investigators. Maejima Y, et al. Among authors: ono y. Circ J. 2011;75(3):589-95. doi: 10.1253/circj.cj-10-0804. Epub 2011 Jan 14. Circ J. 2011. PMID: 21242642 Free article. Clinical Trial.
3,696 results